Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Short-term Combined Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection and/or Early Treatment, Who do Not Fulfil IWCLL Treatment Criteria

Trial Profile

Short-term Combined Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection and/or Early Treatment, Who do Not Fulfil IWCLL Treatment Criteria

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 10 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Acalabrutinib (Primary) ; Venetoclax (Primary)
  • Indications Chronic lymphocytic leukaemia; Infections
  • Focus Proof of concept; Therapeutic Use
  • Acronyms PreVent-ACaLL

Most Recent Events

  • 15 Jun 2023 Results (n=118) clinically validating the predictive performance of CLL-TIM identifying newly diagnosed patients with high risk of infection and/or treatment as part of this study, presented at the 28th Congress of the European Haematology Association
  • 10 Feb 2020 Status changed from not yet recruiting to recruiting.
  • 06 Nov 2019 According to trial design released in 61st Annual Meeting and Exposition of the American Society of Hematology, first patient enrollment in trial was planned for September 2019 and primary outcome expected in 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top